Graft Failure

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Swedish Orphan Biovitrum
1 program
1
EmapalumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT04731298TerminatedEst. Apr 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Swedish Orphan BiovitrumEmapalumab

Clinical Trials (1)

NCT04731298Swedish Orphan BiovitrumEmapalumab

Study to Investigate the Pharmacokinetics, Pharmacodynamics and Assess the Efficacy and Safety to Support Dose Selection of Emapalumab in Pre-empting Graft Failure in Patients at High Risk After HSCT.

Start: May 2021Est. completion: Apr 2022
Phase 2Terminated

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space